Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05945823
Title Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Taiho Oncology, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU


No variant requirements are available.